MIDLOTHIAN, Scotland, Oct. 3 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) and Viragen International, Inc. (OTC Bulletin Board: VGNI) today
announced the promotion of Karen Jervis, Ph.D., MBA, to the position of Vice
President and Managing Director of Viragen (Scotland) Ltd. (VSL). VSL is a
wholly-owned subsidiary of VGNI.
"Dr. Jervis has continually distinguished herself among management and
scientific staff at the Viragen companies, and we have come to rely upon her
judgment on a wide variety of matters," stated Viragen's President and CEO,
Mr. Charles A. Rice. "Her understanding and passion for our technologies and
people are of significant importance as we move from research into development
of these exciting opportunities."
Dr. Jervis previously served as Director of Product Development,
representing the Company and its products in global Business Development
matters. She obtained her Ph.D. in Protein Biochemistry from the University
of Glasgow and MBA from the University of Edinburgh. Dr. Jervis will report
directly to Mr. Rice in her new position and will be responsible for VSL.
Dr. Jervis commented, "I am extremely appreciative in accepting this
appointment, as it is a privilege and pleasure to work with our incredibly
talented and dedicated VSL team, and together we look forward to delivering
key results that advance Viragen's innovative product and technology pipeline.
Our vision and goals include positioning Viragen as a global leader and, most
importantly, delivering new technologies that can save and enhance patients'
lives."
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
Viragen is publicly-traded on the American Stock Exchange (VRA).
Viragen's majority-owned subsidiary, Viragen International, Inc., is publicly-
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer
Research Technology UK, Oxford BioMedica Plc, University of Nottingham (U.K.),
America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com .
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20051003/FLM014
http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
